UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 16, 2018

Novelion Therapeutics Inc.

(Exact Name of Registrant as specified in its charter)

c/o Norton Rose Fulbright

1800 - 510 West Georgia Street, Vancouver, BC V6B 0M3 Canada

(Address of principal executive offices)

Registrant’s telephone number, including area code: (877) 764-3131

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 16, 2018, Jeffrey Hackman notified Novelion Therapeutics Inc. (the “Company”) that he would be resigning as the Company’s Interim Chief Executive Officer and Chief Operating Officer.  Mr. Hackman’s resignation took effect on November 19, 2018.

On November 19, 2018, the Company’s Board of Directors appointed Benjamin Harshbarger, the Company’s General Counsel, to serve as the Company’s Interim Chief Executive Officer (and its principal executive officer), effectively immediately.

Biographical information for Mr. Harshbarger can be found in the press release attached as Exhibit 99.1, which biographical information contained in paragraph three thereof is incorporated into this Item 5.02 by reference.  Mr. Harshbarger’s compensation in connection with his appointment as Interim Chief Executive Officer will be disclosed in a subsequent Current Report on Form 8-K, or by an amendment to this Current Report on Form 8-K, within four business days of determination.

Item 7.01 Regulation FD Disclosure.

A copy of the press release announcing the management changes above is furnished with this report as Exhibit 99.1.

Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall the information therein be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing, including as specifically referenced in Item 5.02 above solely as to Mr. Harshbarger’s biographical information.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  November 20, 2018

3